OCU310, currently in Phase 3 clinical development, is a differentiated, topical therapy being developed for dry eye disease. It is a proprietary OcuNanoE™ formulation of the anti-nociceptive and anti-inflammatory drug brimonidine, an FDA-approved drug with established safety for ocular use, enabling Ocugen to develop OCU310 under the accelerated 505(b)(2) regulatory pathway. OcuNanoE – Ocugen’s ONE Platform™ is designed to enhance efficacy by prolonging retention of this potent anti-inflammatory drug on the eye surface, and unlike other ophthalmic emulsion products, it also allows OCU310 to be sterile filtered, in single-use vials, without the need for added preservatives.
Ocugen has recently completed the first Phase 3 clinical trial of OCU310. Ocugen is waiting for a full dataset from this trial and will provide an update once a full analysis is completed.
About Dry Eye Disease
Dry eye disease is a common yet under-diagnosed ocular disorder. According to the National Eye Institute, experts estimate that dry eye syndrome affects millions of adults in the United States.1 One estimate reports that up to 30 million Americans suffer from dry eye symptoms while a recent study suggests that over 16 million adults in the US have diagnosed dry eye disease.2,3
Its prevalence increases with age, and is more common in women, especially women entering menopause or pregnancy due to associated hormone imbalances that can cause ocular inflammation and tear film abnormalities.
The most common causes of dry eye disease are contact lens usage, autoimmune disorders, systemic drug effects, and refractive surgery, which can lead to aberrant production and stability of tear film. The resulting damage to the ocular surface is correlated with the common signs and symptoms of dry eye disease: eye redness, ocular pain, burning and stinging sensation, foreign body sensation, itchy or scratchy eye sensation, tired eyes, enhanced eye pressure, and painful mucous discharge.
There are only two FDA-approved products for dry eye disease: Restasis® (cyclosporine ophthalmic emulsion) and Xiidra® (lifitegrast ophthalmic solution), which combined address only about 1 million of the 16 million diagnosed patients today. Given the complexity, severity, and frequency of dry eye disease, and given the limited modes of action of currently approved products, there remains a medical need for new dry eye therapies, particularly ones with multiple modes of action that may be effective for a wider patient population and are safe and well tolerated for acute as well as long-term daily use.
1 National Eye Institute website, https://nei.nih.gov/health/dryeye/dryeye (accessed Oct 20, 2017)
2 Market Scope. Report on the Global Dry Eye Market. St. Louis, MO: Market Scope; 2004.
3 Farrand K. et al, American Journal of Ophthalmology, Oct 2017